Citations 12

Dysregulated Tricarboxylic Acid Cycle Metabolism Is Associated With Right Ventricular Maladaptation in Pulmonary Vascular Disease

Journal of the American Heart Association | May 22, 2025 | Volume: 14 | Issue: 11 | Pages: No page available

10.1161/jaha.124.041127 | PMID 40401597

Background Right ventricular (RV) maladaptation to elevated pulmonary afterload is the primary determinant of outcomes in pulmonary artery (PA) hypertension; however, the pathobiological mechanisms underlying RV decompensation remain poorly understood. Methods We performed global untargeted metabolomics on plasma from 55 patients who underwent gold‐standard RV‐PA coupling measurements using multibeat pressure volume loop assessment in a single‐center cohort and from 1027 patients with coupling surrogate measurements in a larger multicenter cohort, the PVDOMICS (Pulmonary Vascular Disease Phenomics) study. Age and sex‐adjusted linear regression was performed to identify associations between metabolites and coupling metrics. Additionally, we performed a metabolic flux analysis using gene expression data from RV tissue in an independent cohort of 32 patients. Partial least squares–discriminant analysis was used to identify metabolites and reactions characteristic of the decompensated RV. Results RV‐PA coupling was negatively associated with tricarboxylic acid (TCA) cycle intermediate levels. Specifically, plasma α‐ketoglutarate and fumarate were significantly associated with all coupling metrics in both cohorts. Metabolic flux analysis indicated that decompensated RVs exhibited aberrant TCA cycle activity, including reduced acetyl coenzyme A entry and increased lactate elimination, suggesting a shift from the TCA cycle toward glycolysis at the RV tissue level. Conclusions We identify an association between circulating TCA cycle intermediate levels and RV‐PA uncoupling in 2 independent cohorts, and dysregulated TCA cycle metabolism in decompensated PA hypertension RVs, suggesting that aberrant TCA cycle metabolism could represent a hallmark of RV maladaptation in PA hypertension. Further study of this pathway is warranted to develop novel biomarkers of RV function or RV‐targeted therapies.
Demographic, Hemodynamic, Health-related Quality of Life, and Longitudinal Outcomes Differences Between Connective Tissue Disease-associated and Idiopathic PAH (Pulmonary Arterial Hypertension): The Pulmonary Hypertension Association Registry

A97. IT'S (NOT) A SMALL WORLD: MOLECULAR AND PHYSIOLOGIC EPIDEMIOLOGY IN PAH | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A2753-A2753

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2753

Pulmonary Hypertension and Anastrozole (Phantom): A Randomized Clinical Trial

D106. HOT OFF THE PRESSES! LATE BREAKERS IN PULMONARY VASCULAR DISEASE | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A6727-A6727

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a6727

Medication Non-adherence and Health-related Outcomes in Patients With Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry (PHAR)

A26. PRECISION-BASED APPROACHES TO PULMONARY VASCULAR DISEASE | May 1, 2023 | Volume: No volume available | Issue: No issue available | Pages: A1186-A1186

10.1164/ajrccm-conference.2023.207.1_meetingabstracts.a1186

Health-Related Quality of Life in Those At-Risk for and with Pulmonary Hypertension in PVDOMICS

TP86. TP086 WHILE MY GUITAR GENTLY WEEPS - NOVEL EPIDEMIOLOGIC STUDIES IN PULMONARY VASCULAR DISEASE | May 4, 2021 | Volume: No volume available | Issue: No issue available | Pages: A3706-A3706

10.1164/ajrccm-conference.2021.203.1_meetingabstracts.a3706

Hospitalization in Connective Tissue Disease Associated Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry

B55. POT POURRI OF THE TOP CLINICAL STUDIES IN PULMONARY HYPERTENSION | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A3788-A3788

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a3788

Quality of Life of Patients with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) and Idiopathic Pulmonary Arterial Hypertension (IPAH): The Pulmonary Hypertension Association Registry (PHAR)

C104. LATEST CLINICAL INVESTIGATIONS IN ACUTE AND CHRONIC THROMBOEMBOLISM DISORDERS OF THE PULMONARY CIRCULATION | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A6048-A6048

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a6048

Health Disparities and Treatment Patterns in Portopulmonary Hypertension and Idiopathic Pulmonary Arterial Hypertension: An Analysis of the Pulmonary Hypertension Association Registry

B27. UP-TO-DATE PAH ASSESSMENT AND MANAGEMENT | July 7, 2020 | Volume: No volume available | Issue: No issue available | Pages: A2906-A2906

10.1164/ajrccm-conference.2020.201.1_meetingabstracts.a2906

Nurse Staffing and the Quality of Life and Outcomes of Patients with Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry

C52. USE YOUR ILLUSION II: CLINICAL RESEARCH IN PAH | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5100-A5100

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5100

Intersecting Identities and Patient Outcomes in Pulmonary Arterial Hypertension: Early Results in Derivation of a Model Using the Pulmonary Hypertension Association Registry (PHAR)

C52. USE YOUR ILLUSION II: CLINICAL RESEARCH IN PAH | August 26, 2019 | Volume: No volume available | Issue: No issue available | Pages: A5098-A5098

10.1164/ajrccm-conference.2019.199.1_meetingabstracts.a5098